AllNews'Strides Pharma Science' - 7 News Result(s)Stocks To Watch: Coal India, Strides Pharma, NHPC, Jaiprakash Power VenturesBusiness | Edited by Peter Noronha | Tuesday June 15, 2021 Coal India reported a 0.8 per cent decline in consolidated profit to Rs 4,588.96 crore in the quarter ended March 2021 from Rs 4,625.7 crore in the same quarter ended last year www.ndtv.com/businessStrides Pharma Surges On USFDA Nod For Headache DrugBusiness | Edited by Abhishek Vasudev | Thursday July 9, 2020 Strides Pharma shares surged as much as 5% after it got approval from USFDA for Butalbital, Acetaminophen, Caffeine, andCodeine Phosphate Capsules. www.ndtv.com/businessSun Pharma To Test Pancreatitis Drug In COVID-19 PatientsBusiness | Reuters | Saturday May 30, 2020 The company joins other drugmakers Glenmark and Strides Pharma Science that are conducting trials in India for potential drugs for COVID-19. www.ndtv.com/businessStrides Pharma To Conduct Trials In India For Potential COVID-19 DrugBusiness | Reuters | Thursday May 21, 2020 Bengaluru-based Strides Pharma Science has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country. www.ndtv.com/businessBuy Strides Pharma Science, HDFC Bank August Futures, Says Choice BrokingBusiness | Edited By Abhishek Vasudev | Friday August 9, 2019 After a healthy correction from its all-time high, the Nifty has managed to take a support at its 100 weeks moving average which indicates a bounce back move in the Index. www.ndtv.com/businessWhy Shares Of This Bengaluru-Based Drug Maker Plunged Over 8% TodayBusiness | NDTV Profit Team | Wednesday July 17, 2019 US FDA had inspected Strides Pharma's drug manufacturing facility in Puducherry from January 28 to February 5, 2019 and said that the company was caught trying to dispose quality-control records. www.ndtv.com/businessUS-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 OthersBusiness | Monday September 15, 2014 US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India. www.ndtv.com/business'Strides Pharma Science' - 7 News Result(s)Stocks To Watch: Coal India, Strides Pharma, NHPC, Jaiprakash Power VenturesBusiness | Edited by Peter Noronha | Tuesday June 15, 2021 Coal India reported a 0.8 per cent decline in consolidated profit to Rs 4,588.96 crore in the quarter ended March 2021 from Rs 4,625.7 crore in the same quarter ended last year www.ndtv.com/businessStrides Pharma Surges On USFDA Nod For Headache DrugBusiness | Edited by Abhishek Vasudev | Thursday July 9, 2020 Strides Pharma shares surged as much as 5% after it got approval from USFDA for Butalbital, Acetaminophen, Caffeine, andCodeine Phosphate Capsules. www.ndtv.com/businessSun Pharma To Test Pancreatitis Drug In COVID-19 PatientsBusiness | Reuters | Saturday May 30, 2020 The company joins other drugmakers Glenmark and Strides Pharma Science that are conducting trials in India for potential drugs for COVID-19. www.ndtv.com/businessStrides Pharma To Conduct Trials In India For Potential COVID-19 DrugBusiness | Reuters | Thursday May 21, 2020 Bengaluru-based Strides Pharma Science has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country. www.ndtv.com/businessBuy Strides Pharma Science, HDFC Bank August Futures, Says Choice BrokingBusiness | Edited By Abhishek Vasudev | Friday August 9, 2019 After a healthy correction from its all-time high, the Nifty has managed to take a support at its 100 weeks moving average which indicates a bounce back move in the Index. www.ndtv.com/businessWhy Shares Of This Bengaluru-Based Drug Maker Plunged Over 8% TodayBusiness | NDTV Profit Team | Wednesday July 17, 2019 US FDA had inspected Strides Pharma's drug manufacturing facility in Puducherry from January 28 to February 5, 2019 and said that the company was caught trying to dispose quality-control records. www.ndtv.com/businessUS-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 OthersBusiness | Monday September 15, 2014 US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India. www.ndtv.com/businessYour search did not match any documentsA few suggestionsMake sure all words are spelled correctlyTry different keywordsTry more general keywordsCheck the NDTV Archives:https://archives.ndtv.com